Compass Therapeutics (NASDAQ:CMPX) Cut to “Hold” at Leerink Partnrs

Leerink Partnrs downgraded shares of Compass Therapeutics (NASDAQ:CMPX) from a strong-buy rating to a hold rating in a research note issued to investors on Friday morning,Zacks.com reports.

Several other research analysts have also recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Compass Therapeutics in a research report on Monday, November 11th. Leerink Partners lowered shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $5.00 to $4.00 in a report on Friday. LADENBURG THALM/SH SH upgraded shares of Compass Therapeutics from a “neutral” rating to a “buy” rating and set a $5.00 price target for the company in a research report on Monday, September 16th. Finally, Wedbush reiterated an “outperform” rating and issued a $8.00 price objective on shares of Compass Therapeutics in a research report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $6.75.

Compass Therapeutics Stock Performance

Shares of Compass Therapeutics stock opened at $1.35 on Friday. The stock’s 50-day simple moving average is $1.75 and its 200 day simple moving average is $1.41. Compass Therapeutics has a 52-week low of $0.77 and a 52-week high of $2.34. The stock has a market capitalization of $185.75 million, a P/E ratio of -3.65 and a beta of 0.92.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. Equities research analysts forecast that Compass Therapeutics will post -0.37 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Hedge funds have recently made changes to their positions in the business. Geode Capital Management LLC raised its stake in Compass Therapeutics by 0.8% in the third quarter. Geode Capital Management LLC now owns 2,309,778 shares of the company’s stock worth $4,251,000 after buying an additional 19,095 shares in the last quarter. Barclays PLC grew its position in shares of Compass Therapeutics by 195.4% in the 3rd quarter. Barclays PLC now owns 170,245 shares of the company’s stock worth $314,000 after buying an additional 112,614 shares during the period. XTX Topco Ltd bought a new position in shares of Compass Therapeutics in the 3rd quarter worth about $37,000. The Manufacturers Life Insurance Company purchased a new position in Compass Therapeutics during the 3rd quarter valued at about $79,000. Finally, Intech Investment Management LLC bought a new stake in Compass Therapeutics during the third quarter worth about $30,000. 68.43% of the stock is owned by hedge funds and other institutional investors.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.